Join Growin Stock Community!

Nautilus biotechnology, inc.NAUT.US Overview

US StockHealthcare
(No presentation for NAUT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NAUT AI Insights

NAUT Overall Performance

NAUT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NAUT Recent Performance

-4.34%

Nautilus biotechnology, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NAUT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NAUT Key Information

NAUT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NAUT Profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Price of NAUT

NAUT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NAUT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.47
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.81
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.47
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.81
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NAUT's latest earnings report released?

    The most recent financial report for Nautilus biotechnology, inc. (NAUT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NAUT's short-term business performance and financial health. For the latest updates on NAUT's earnings releases, visit this page regularly.

  • How much debt does NAUT have?

    As of the end of the reporting period, Nautilus biotechnology, inc. (NAUT) had total debt of 30.02M, with a debt ratio of 0.16. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NAUT have?

    At the end of the period, Nautilus biotechnology, inc. (NAUT) held Total Cash and Cash Equivalents of 12.39M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NAUT's EPS continuing to grow?

    According to the past four quarterly reports, Nautilus biotechnology, inc. (NAUT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.11. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NAUT?

    Nautilus biotechnology, inc. (NAUT)'s Free Cash Flow (FCF) for the period is -12.62M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 13.35% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.